Slate Therapeutics

Slate Therapeutics: Pioneering Long-Acting Drug Delivery for CRS, Neurology & Obesity: At Slate Therapeutics, we are revolutionizing long-acting drug delivery with innovative sinus-to-brain and oral extended-release technologies. Our proprietary platform enables weeks-to-months of controlled drug release, transforming treatment for chronic rhinosinusitis (CRS), neurological disorders, and metabolic diseases—including obesity. Our Drug Delivery Platforms 🔹 Sinus Drug Delivery: Our proprietary formulation provides over 45 days of sustained release when placed in the sinus, offering a game-changing approach for CRS and direct-to-brain drug delivery via the olfactory pathway. 🔹 Long-Acting Oral Drug Delivery (Obesity & Metabolic Disease): Expanding beyond CRS, we are developing an extended-release oral platform designed to enhance drug efficacy, reduce dosing frequency, and improve patient adherence. Our initial focus is on obesity and metabolic syndromes, addressing the rapidly growing demand for next-generation weight loss treatments.